Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...
The trial laid the foundation for the Comparative Immunotherapy Program — a program launched a year ago to tap into Penn’s ...
Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
At Ochsner Cancer Center of Acadiana, people diagnosed with blood cancers find more than the latest treatments — they also ...
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 ...
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback